P24 Cardioprotective effects of S-propargyl-cysteine controlled release formulation to heart failure rats after myocardial infarction and the possible involved mechanism
作者: Chengrong HuangJuntao KanShujun WangYizhun Zhu
作者单位: 1School of Pharmacy, Fudan University, Shanghai 201203, China
2School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China
刊名: Nitric Oxide, 2012, Vol.27 , pp.S23-S23
来源数据库: Elsevier Journal
DOI: 10.1016/j.niox.2012.08.025
原始语种摘要: Background(#br)Heart failure (HF) is one of the most serious health issues in both developed and developing countries that causes millions of people suffering. In recent years, as a significant endogenous gasotransmitter, hydrogen sulfide has been reported to play vital roles on cardiovascular system. S-Propargyl-cysteine (SPRC), a novel endogenous hydrogen sulfide donor, is proved to mediate the formation of hydrogen sulfide to inhibit myocardial apoptosis and reduce oxidative stress to protect against acute myocardial ischemia. In order to produce more stable and sustaining hydrogen sulfide, we modified the dosage form to get SPRC controlled release formulation (SPRC (RS)). In this work, we elucidated the possible cardioprotective effects of this formulation on HF rats and investigated...
全文获取路径: Elsevier  (合作)
影响因子:3.265 (2012)

  • infarction 梗塞
  • myocardial 心肌的
  • controlled 受控
  • cysteine 胖胱氨酸
  • propargyl 炔丙基
  • heart 心脏
  • formulation 配方
  • involved 涉及
  • failure 破坏
  • release 释放